Literature DB >> 3878029

Vaccinia virus proteins on the plasma membrane of infected cells. III. Infection of peritoneal macrophages.

R J Natuk, J A Holowczak.   

Abstract

Primary macrophage cultures were prepared from the peritoneal exudate cell population harvested from mice challenged intraperitoneally with saline, thioglycollate, or vaccinia virus. Vaccinia virus was adsorbed and penetrated into primary macrophages and L-cells with similar kinetics. As evidenced by the expression of some "early" virus-specified proteins, partial uncoating and activation of the virion-associated DNA-dependent RNA polymerase occurred in the infected macrophages. Subsequently, the viral replication cycle in macrophages was aborted; with time after infection, viral DNA and virion proteins initially associated with infected cells could be detected in an acid-soluble form in the medium harvested from infected macrophage cultures. The results suggest that at the time that the final stages of virus uncoating should have occurred, intracellular subviral particles were, instead, degraded in the infected, primary macrophages. Viral DNA synthesis could not be measured in vaccinia virus-infected macrophages, no "late" virus functions were expressed, and progeny virions were not assembled. As measured by the binding of antiviral-antibody-125I-protein A complexes to the surface of vaccinia virus-infected cells, the expression of virus-specified antigens on the surfaces of infected macrophages was significantly reduced and never exceeded that measured at 2 hr after infection on the surfaces of infected L-cells. The expression of virus-specified polypeptides with mol mass of 48-50, 45-46, 36-37, and 25 kDa on the plasma membranes of vaccinia virus-infected, thioglycollate-elicited macrophages, rendered the infected macrophages susceptible to lysis by vaccinia virus-specific cytotoxic T-cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3878029     DOI: 10.1016/0042-6822(85)90138-2

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  11 in total

1.  The vaccinia virus superoxide dismutase-like protein (A45R) is a virion component that is nonessential for virus replication.

Authors:  F Almazán; D C Tscharke; G L Smith
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

Review 2.  Initiation of primary anti-vaccinia virus immunity in vivo.

Authors:  Matthew A Fischer; Christopher C Norbury
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

3.  In vivo effects of a recombinant vaccinia virus expressing a mouse mammary tumor virus superantigen.

Authors:  C Krummenacher; H Diggelmann; H Acha-Orbea
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

Review 4.  Smallpox vaccines: targets of protective immunity.

Authors:  Bernard Moss
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

5.  Wiskott-Aldrich syndrome protein is needed for vaccinia virus pathogenesis.

Authors:  Susana Guerra; Miguel Aracil; Raquel Conde; Antonio Bernad; Mariano Esteban
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

6.  Ectromelia virus replication in major target organs of innately resistant and susceptible mice after intravenous infection.

Authors:  D G Brownstein; P N Bhatt; L Gras
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

7.  Attenuation of vaccinia virus by the expression of human Flt3 ligand.

Authors:  Kamila Zurkova; Petr Hainz; Jitka Krystofova; Luda Kutinova; Miloslav Sanda; Sarka Nemeckova
Journal:  Virol J       Date:  2010-05-26       Impact factor: 4.099

8.  Ectromelia virus RING finger protein is localized in virus factories and is required for virus replication in macrophages.

Authors:  T G Senkevich; E J Wolffe; R M Buller
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

Review 9.  Poxvirus pathogenesis.

Authors:  R M Buller; G J Palumbo
Journal:  Microbiol Rev       Date:  1991-03

10.  Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine.

Authors:  V Bronte; M W Carroll; T J Goletz; M Wang; W W Overwijk; F Marincola; S A Rosenberg; B Moss; N P Restifo
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.